Patents by Inventor Martin Johannes Loessner
Martin Johannes Loessner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148806Abstract: The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.Type: ApplicationFiled: June 30, 2023Publication date: May 9, 2024Applicant: ETH ZurichInventors: Samuel Nando KILCHER, Matthew Stephen DUNNE, Susanne Andrea MEILE, Jiemin DU, Martin Johannes LOESSNER
-
Publication number: 20220184187Abstract: The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.Type: ApplicationFiled: March 7, 2022Publication date: June 16, 2022Applicant: Micreos Human Health B.V.Inventors: Mark Leonard Offerhaus, Fritz Eichenseher, Martin Johannes Loessner
-
Patent number: 11339386Abstract: The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.Type: GrantFiled: November 9, 2020Date of Patent: May 24, 2022Assignee: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20210130802Abstract: The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.Type: ApplicationFiled: November 9, 2020Publication date: May 6, 2021Applicant: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Patent number: 10829749Abstract: The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.Type: GrantFiled: September 12, 2016Date of Patent: November 10, 2020Assignee: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20200095558Abstract: The present invention related to a method for producing or propagating an engineered bacteriophage, comprising the steps of: providing a functional synthetic genome of an engineered bacteriophage being able to infect a target bacterium; providing a recipient bacterium; transforming the recipient bacterium with the functional synthetic genome in a transformation step, yielding a transformed recipient bacterium; incubating the transformed recipient bacterium in a first incubation step, wherein the engineered bacteriophage is propagated within the transformed recipient bacterium; and further incubating the transformed recipient bacterium or the propagated engineered bacteriophage released from the transformed recipient bacterium with the target bacterium in a second incubation step, wherein the propagated engineered bacteriophage infects the target bacterium and is further propagated within the target bacterium, and wherein the recipient bacterium is a cell wall-deficient bacterium.Type: ApplicationFiled: February 8, 2018Publication date: March 26, 2020Applicant: ETH ZurichInventors: Martin Johannes Loessner, Samuel Kilcher, Patrick Studer
-
Publication number: 20190374621Abstract: The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.Type: ApplicationFiled: June 13, 2019Publication date: December 12, 2019Applicant: Micreos Human Health B.V.Inventors: Mark Leonard Offerhaus, Fritz Eichenseher, Martin Johannes Loessner
-
Patent number: 10435669Abstract: The invention relates to the field of microbiology, specifically to a bacteriophage, polypeptide and a corresponding polynucleotide, a nucleic acid molecule and/or vector and/or cell comprising such polynucleotide, a composition comprising said bacteriophage, polypeptide, polynucleotide, construct, vector and/or cell, preferably for preventing, treating or diagnosing contamination with and/or a condition in an individual related to Salmonella. The invention further relates to an antimicrobial composition for medical use or for use as a food additive or as a disinfectant, or for detecting bacteria, preferably in a diagnostic application, wherein said antimicrobial composition comprises a bacteriophage, polypeptide, corresponding polynucleotide, construct and/or vector and/or cell comprising such polypeptide and/or composition according to the present invention.Type: GrantFiled: May 7, 2013Date of Patent: October 8, 2019Assignee: MICREOS B.V.Inventors: Martin Johannes Loessner, Steven Hagens, Albert Johannes Hendrikus Slijkhuis, Jochen Achim Klumpp, Roger Marti
-
Patent number: 10357547Abstract: The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.Type: GrantFiled: July 10, 2014Date of Patent: July 23, 2019Assignee: Micreos Human Health B.V.Inventors: Mark Leonard Offerhaus, Fritz Eichenseher, Martin Johannes Loessner
-
Patent number: 10174300Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.Type: GrantFiled: June 2, 2016Date of Patent: January 8, 2019Assignee: MICREOS HUMAN HEALTH B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20180237760Abstract: The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.Type: ApplicationFiled: September 12, 2016Publication date: August 23, 2018Applicant: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Patent number: 9789167Abstract: The invention relates to the field of microbiology, specifically to a combination of a source of a first enzymatic active domain and a source of a second enzymatic active domain and to a composition comprising said combination. The invention further relates to a composition comprising said combination for use as a medicament, to the use of said composition as an antimicrobial agent and to a method for controlling microbial contamination in a food- or feed product, on and/or in food- or feed processing equipment, on and/or in food- or feed containers.Type: GrantFiled: May 7, 2013Date of Patent: October 17, 2017Assignee: MICREOS HUMAN HEALTH B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20170143778Abstract: The present invention relates to a method of feeding an animal to improve growth efficiency.Type: ApplicationFiled: June 24, 2015Publication date: May 25, 2017Applicant: Micreos B.V.Inventors: Johan Frans Willem Nuboer, Steven Hagens, Martin Johannes Loessner, Mark Leonard Offerhaus
-
Publication number: 20160369255Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.Type: ApplicationFiled: June 2, 2016Publication date: December 22, 2016Applicant: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Patent number: 9382298Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.Type: GrantFiled: May 4, 2011Date of Patent: July 5, 2016Assignee: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20150125424Abstract: The invention relates to the field of microbiology, specifically to a bacteriophage, polypeptide and a corresponding polynucleotide, a nucleic acid molecule and/or vector and/or cell comprising such polynucleotide, a composition comprising said bacteriophage, polypeptide, polynucleotide, construct, vector and/or cell, preferably for preventing, treating or diagnosing contamination with and/or a condition in an individual related to Salmonella. The invention further relates to an antimicrobial composition for medical use or for use as a food additive or as a disinfectant, or for detecting bacteria, preferably in a diagnostic application, wherein said antimicrobial composition comprises a bacteriophage, polypeptide, corresponding polynucleotide, construct and/or vector and/or cell comprising such polypeptide and/or composition according to the present invention.Type: ApplicationFiled: May 7, 2013Publication date: May 7, 2015Applicant: Micreos B.V.Inventors: Martin Johannes Loessner, Steven Hagens, Albert Johannes Hendrikus Slijkhuis, Jochen Achim Klumpp, Roger Marti
-
Publication number: 20150118189Abstract: The invention relates to the field of microbiology, specifically to a combination of a source of a first enzymatic active domain and a source of a second enzymatic active domain and to a composition comprising said combination. The invention further relates to a composition comprising said combination for use as a medicament, to the use of said composition as an antimicrobial agent and to a method for controlling microbial contamination in a food- or feed product, on and/or in food- or feed processing equipment, on and/or in food- or feed containers.Type: ApplicationFiled: May 7, 2013Publication date: April 30, 2015Applicant: MICREOS HUMAN HEALTH B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher
-
Publication number: 20140127168Abstract: The invention relates to a polypeptide, a corresponding nucleic acid molecule, a construct and/or vector and/or cell comprising such nucleic acid molecule and/or a composition comprising said polypeptide, nucleic acid molecule, construct, vector and/or cell. The invention further relates to such composition for medical use, preferably for use in treating an infectious disease. Furthermore, the invention relates to the use of said polypeptide, nucleic acid molecule, construct, vector, cell and/or composition as an antimicrobial, preferably as a food additive or disinfectant, or for detecting bacteria, preferably in a diagnostic application.Type: ApplicationFiled: May 4, 2011Publication date: May 8, 2014Applicant: Micreos Human Health B.V.Inventors: Martin Johannes Loessner, Fritz Eichenseher